A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and higher scores indicate better functioning. A mixed-model repeated-measures analysis was used. RESULTS: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board. At termination, there were 189 patients in the group receiving placebo, 153 patients in the group receiving 100 mg of semagacestat, and 121 patients in the group receiving 140 mg of semagacestat. The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). Laboratory abnormalities included reduced levels of lymphocytes, T cells, immunoglobulins, albumin, total protein, and uric acid and elevated levels of eosinophils, monocytes, and cholesterol; the urine pH was also elevated. CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, participants experienced adverse reactions such as gastrointestinal symptoms, skin cancer, and infections, which are speculated to be related to the inhibition of other γ-secretase substrates, including notch, CD44, ErbB4, and cadherin.438–441”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [438]
In the citing paper
“Disappointingly, the use of γ-secretase inhibitors (GSIs) has shown limited efficacy in treating Alzheimer's disease [113].”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [113]
In the citing paper
“Several drugs that have shown promising results in Alzheimer mouse models have failed to prevent cognitive decline in late-phase clinical trials87–89.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [88]
In the citing paper
“However, with the failures or unsatisfactory efficacy of drugs anti-Aβ [9, 208–211], the development of drugs targeting other targets is increasing, such as anti-tau pathology and anti-neuroinflammation [212].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [208]
In the citing paper
“Semagacestat was the first GSI to enter a phase 3 trial for AD. However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Doody et al., 2013
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
Self-citationClinical Gerontology: A Guide to Assessment and Intervention
Brink, T. L. (1986) · Medical Entomology and Zoology · Cited by 594
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Research works printed but not linked: 2
- Wimo A, Wetterholm A-L, Mastey V, Winbald B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. The health economics of dementia. London: Wiley, 1998:465-99.
- Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 701–800 of 1,002
Topiwala, A., Suri, S., Allan, C. L., Valkanova, V., Filippini, N., Sexton, C. E., Heise, V., Zsoldos, E., Mahmood, A., Singh‐Manoux, A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211273 · Cited by 16
Arbo, B. D., Ribeiro, M. F. M., & García‐Segura, L. M. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100943 · Cited by 16
Amyloid-beta Targeted Therapeutic Approaches for Alzheimer’s Disease: Long Road Ahead
Dai, Y., Lei, C., Zhang, Z., Qi, Y., Lao, K., & Gou, X. (2022) · Current Drug Targets · doi:10.2174/1389450123666220421124030 · Cited by 16
γ-Secretase: once and future drug target for Alzheimer’s disease
Wolfe, M. S. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2277350 · Cited by 16
“However, Eli Lilly candidate sema-gacestat failed in Phase 3 clinical trials, with adverse events similar to what was observed in mice [10].”
BackgroundMeyer, P., Savard, M., Poirier, J., Morgan, D., Breitner, J. C. S., & Initiative, A. D. N. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.05.007 · Cited by 16
Boylan, J., Byers, E., & Kelly, D. F. (2023) · Medical Research Archives · doi:10.18103/mra.v11i6.3994 · Cited by 17
“Notably, GSIs have the potential to impair Notch regulation in healthy cells as well as in tumor cells 222,223 .”
BackgroundAn inclusive study of recent advancements in Alzheimer's disease: A comprehensive review
Singh, S., Mahajan, M., Kumar, D., Singh, K., Chowdhary, M., & Amit (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102369 · Cited by 17
Modulation of Notch Signaling by Small-Molecular Compounds and Its Potential in Anticancer Studies
Czerwonka, A., Kałafut, J., & Nees, M. (2023) · Cancers · doi:10.3390/cancers15184563 · Cited by 16
“This hypothesis is supported by the observation that γ -secretase inhibitors, a class of drugs that reduce Notch signaling, may increase the risk of skin cancer development in patients who have received any of these drugs in clinical studies [71].”
ResultAdvances of therapy for Alzheimer's disease: An updated review
Mei, C., Zhan, J., Zhu, S., Zhang, Y., Xiong, C., Wang, J., Xu, Y. J., Zhong, H., & Cheng, J. (2024) · Brain‐X · doi:10.1002/brx2.68 · Cited by 16
Emerging paradigms in Alzheimer's therapy
Agnes Preethy, H., Rajendran, K., Sukumar, A. J., & Krishnan, U. M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176872 · Cited by 18
Pokrzyk, J., Kulczyńska‐Przybik, A., Guzik-Makaruk, E. M., Winkel, I., & Mroczko, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051935 · Cited by 16
Drug therapies in older adults (part 1)
Mukhtar, O., & Jackson, S. H. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-1-47 · Cited by 21
Fu, Y., Zhao, D., Pan, B., Wang, J., Cui, Y., Shi, F., Wang, C., Yin, X., Zhou, X., & Yang, L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150312 · Cited by 18
Karelina, T., Demin, O. O., Demin, O. O., Duvvuri, S., & Nicholas, T. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12249 · Cited by 15
Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease
Abou, M. B., Sun, L., & Wei, H. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200522204722 · Cited by 15
Svedružić, Ž. M., Vrbnjak, K., Martinović, M., & Miletić, V. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040514 · Cited by 16
“The failed clinical trials with semagacestat [7,16,30,31,66] were much more expensive than the failed clinical trials with avagacestat [10,28].”
ResultLyketsos, C. G., Holroyd, K., Fosdick, L., Smith, G. S., Leoutsakos, J., Munro, C. A., Oh, E. S., Drake, K. E., Rosenberg, P., Anderson, W. S., et al. (2015) · Open Access Journal of Clinical Trials · doi:10.2147/oajct.s81542 · Cited by 16
“64–66 Mean ADAS-cog-11 was 17.5 for implanted ADvance participants, and ranged from 19 to 23 in recent Phase III trials.”
InfluentialPohland, M., Hagl, S., Pellowska, M., Wurglics, M., Schubert‐Zsilavecz, M., & Eckert, G. P. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1765-0 · Cited by 16
“However, GSIs have failed in early clinical trials due to adverse side effects possibly because of interference with the Notch signaling pathway [47, 48].”
BackgroundRab21, a Novel PS1 Interactor, Regulates γ-Secretase Activity via PS1 Subcellular Distribution
Sun, Z., Xie, Y., Chen, Y., Yang, Q., Quan, Z., Dai, R., & Qing, H. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0606-3 · Cited by 17
Important advances in Alzheimer’s disease from the use of induced pluripotent stem cells
Majolo, F., Marinowic, D. R., Machado, D. C., & da Costa, J. C. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0501-5 · Cited by 17
Plant-based vaccines for Alzheimer’s disease
Ishiura, S., & Yoshida, T. (2019) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.95.020 · Cited by 15
Gülcan, H. O., & Orhan, İ. E. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200131103524 · Cited by 17
Mota, B. C., Ashburner, N., Abelleira, L. E., Liu, L., Aleksynas, R., Rovati, L. C., Caselli, G., & Sastre, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137320 · Cited by 15
Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy
Seervai, R. N. H., Cho, W. C., Chu, E. Y., Marques-Piubelli, M. L., Ledesma, D. A., Richards, K. N., Heberton, M. M., Nelson, K. C., Nagarajan, P., Torres-Cabala, C. A., et al. (2021) · Journal of Cutaneous Pathology · doi:10.1111/cup.14145 · Cited by 15
Plasma Exchange in Alzheimer's Disease
Rohrer, L., Yünce, M., Montine, T. J., & Shan, H. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.09.005 · Cited by 15
Zhou, D., Lin, Y., Han, Z., Zhang, Z., Lin, L., Lin, S., & Yang, Q. (2024) · Aging and Disease · doi:10.14336/ad.2024.1085 · Cited by 17
Druggable genome screens identify SPP as an antiviral host target for multiple flaviviruses
Qiao, W., Xie, X., Shi, P., Ooi, Y. S., & Carette, J. E. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2421573122 · Cited by 15
“Given the clinical development of γ-secretase inhibitors much has been learned about in vivo toxicity ( 60 , 61 ).”
Targeted γ-Secretase Inhibition To Control the Notch Pathway in Renal Diseases
Juillerat‐Jeanneret, L., Flohr, A., Schneider, M. P., Walter, I., Wyss, J.-C., Kumar, R., Golshayan, D., & Aebi, J. D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00912 · Cited by 15
Clemente, N., Abdine, A., Ubarretxena‐Belandia, I., & Wang, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-30015-6 · Cited by 16
b-Annulated 1,4-dihydropyridines as Notch inhibitors
Gomez‐Galeno, J., Hurtado, C., Cheng, J., Yardımcı, C., Mercola, M. A., & Cashman, J. R. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.002 · Cited by 14
he amyloid hypothesis of Alzheimer's disease: past and present, hopes and disappointments
Litvinenko, I., Emelin, А. Y., Lobzin, V. Y., Kolmakova, K. A., Naumov, K. M., Lupanov, I. A., Киливаева, Г. А., & Alizade, M. (2019) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2019-3-4-10 · Cited by 14
Fighting fire with fire: The immune system might be key in our fight against Alzheimer’s disease
Dujardin, P., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.004 · Cited by 15
Ras and Rab Interactor 3: From Cellular Mechanisms to Human Diseases
Shen, R., Murphy, C. J., Xu, X., Hu, M., Ding, J., & Wu, C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.824961 · Cited by 19
Alves, S. S., da Silva-Júnior, R. M. P., Delfino-Pereira, P., Pereira, M. G. A. G., Vasconcelos, I. C., Schwaemmle, H., Mazzei, R. F., Carlos, M. L., Espreáfico, E. M., Tedesco, A. C., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02810-w · Cited by 16
Zoltowska, K. M., Das, U., Lismont, S., Enzlein, T., Maesako, M., Houser, M. C., Franco, M. L., Özcan, B., Moreira, D. G., Karachentsev, D., et al. (2023) · eLife · doi:10.7554/elife.90690 · Cited by 14
“…semagacestat have been proposed to have contributed to the cognitive alterations observed in semagacestat-treated patients in the failed Phase-3 IDENTITY clinical trial ( Doody et al., 2013 ) and that semagacestat, like A β 42, acts as a high affinity competitor of substrates ( Koch et al., 2023 ).”
BackgroundInfluentialBrain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
Torres, M., Busquets, X., & Escribá, P. V. (2016) · InTech eBooks · doi:10.5772/64757 · Cited by 14
“Furthermore, a worsening of cognition was observed in AD-treated patients [109].”
BackgroundAllix, F., Gembus, V., Coquet, L., Hubert‐Roux, M., Chan, P., Truong, L., Sebban, M., Coadou, G., Oulyadi, H., Papamicaël, C. A., et al. (2018) · ACS Omega · doi:10.1021/acsomega.8b02121 · Cited by 14
A Revisit to Etiopathogenesis and Therapeutic Strategies in Alzheimer’s Disease
Kumar, M., & Bansal, N. (2021) · Current Drug Targets · doi:10.2174/1389450122666211118125233 · Cited by 14
Colin, J., Allouche, A., Chauveau, F., Corbier, C., Gregory, L., Lanhers, M., Claudepierre, T., Yen, F. T., Oster, T., & Malaplate, C. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151110 · Cited by 15
Zhang, X., Wang, W.-A., Jiang, L.-X., Liu, H., Zhang, B., Lim, N. K.-H., Li, Q.-Y., & Huang, F.-D. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3567-16.2017 · Cited by 14
“However, neither the inhibition of A production by using - and -secretase inhibitors (Doody et al., 2013) (www.”
BackgroundMethodHe, P., Xin, W., Schulz, P., & Sierks, M. R. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1597-z · Cited by 15
Moezzi, S.-M.-I., Mozafari, N., Fazel-Hoseini, S.-M., Nadimi-Parashkoohi, S., Abbasi, H., Ashrafi, H., & Azadi, A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00637 · Cited by 13
AI and organoid platforms for brain-targeted theranostics
Ye, R., Zhang, Y., Xu, W., Lai, L. H., Zhang, Z., Chen, Y., & Qin, S. (2025) · Theranostics · doi:10.7150/thno.123243 · Cited by 14
“Traditional drug discovery models have struggled to effectively overcome the BBB and precisely target therapeutic agents to diseased brain regions or cells[3], leading to high clinical trial failure rates for CNS drugs.”
InfluentialMackey-Alfonso, S. E., & Barrientos, R. M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70911 · Cited by 15
“245 Similarly, C1q knockout APP mice exhibited no change in hippocampal total or fibrillar A β deposition at 9, 12, and 16 months of age.”
Nanotechnology Therapy for Alzheimer′s Disease Memory Impairment Attenuation
Ribarič, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031102 · Cited by 13
“However, no successful AD drug for humans has been developed on the basis of either hypothesis [74,83,86].”
BackgroundYamamoto, K., Yamamoto, R., & Kato, N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.660319 · Cited by 15
Conformational Models of APP Processing by Gamma Secretase Based on Analysis of Pathogenic Mutations
Kim, M., & Борисович, Б. И. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413600 · Cited by 13
“However, γ-secretase inhibitors such as, for example, semagacestat (LY-450139), have failed in clinical trials [11,12].”
BackgroundRyan, K. C., Laboy, J. T., & Norman, K. R. (2022) · Antioxidants · doi:10.3390/antiox11091642 · Cited by 13
“However, efforts to treat AD by reducing amyloid plaque load have been clinical failures, with immunotherapies targeting amyloid beta showing no effect on disease progression [79,80].”
BackgroundMartens, A. W. J., Rietveld, J. M., de Boer, R., Peters, F. S., Ngo, A., van Mil, L. W. H. G., de Heer, K., Spaargaren, M., Verkleij, C. P. M., van de Donk, N. W. C. J., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0083 · Cited by 13
“γ-secretase inhibitors have been used in clinical trials for treatment of Alzheimer’s disease (40, 41), as well as multiple types of cancers due to its ability to inhibit Notch activity (42–44).”
MethodNOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications
Deshotels, L., Safa, F. M., & Saba, N. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210280 · Cited by 14
“Gamma secretase inhibitors (GSI) were initially developed for use in Alzheimer’s disease, given the role of gamma secretase in the cleavage of amyloid precursor protein, a key element in disease progression [48,49].”
BackgroundAmyloid cascade hypothesis, tau synthesis, and role of oxidative stress in AD
Vyas, J., Raytthatha, N., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00023-6 · Cited by 13
Kim, J. A., Casalini, T., Brambilla, D., & Leroux, J. (2016) · Scientific Reports · doi:10.1038/srep34297 · Cited by 12
Aβ 1–42 C-terminus fragment derived peptides prevent the self-assembly of the parent peptide
Bansal, S., Maurya, I. K., Shenmar, K., Yadav, N., Thota, C. K., Kumar, V., Tikoo, K., Chauhan, V. S., & Jain, R. (2017) · RSC Advances · doi:10.1039/c6ra26295c · Cited by 13
Guix, F. X., Sartório, C. L., & ILL‐Raga, G. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180089 · Cited by 13
Shao, Y., & Xu, T. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-6601 · Cited by 13
“Neuronal damage is currently thought to be a key pathological response in the pathogenesis of AD (3,4,13-16).”
BackgroundNew Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Savoia, P., Cremona, O., & Fava, P. (2015) · Current Drug Targets · doi:10.2174/1389450116666150806123717 · Cited by 17
Clinical trials in Alzheimer's disease
Delrieu, J., & Vellas, B. J. (2015) · Wiley eBooks · doi:10.1002/9781118323434.ch9 · Cited by 13
Self-citationCharacterization of SPP inhibitors suppressing propagation of HCV and protozoa
Hirano, J., Okamoto, T., Sugiyama, Y., Suzuki, T., Kusakabe, S., Tokunaga, M., Fukuhara, T., Sasai, M., Tougan, T., MATSUNAGA, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712484114 · Cited by 13
BRI2 as an anti-Alzheimer gene
Matsuda, S., & Senda, T. (2018) · Medical Molecular Morphology · doi:10.1007/s00795-018-0191-1 · Cited by 13
Proteomic profiling dataset of chemical perturbations in multiple biological backgrounds
Dele-Oni, D. O., Christianson, K. E., Egri, S. B., Jácome, A. S. V., DeRuff, K. C., Mullahoo, J., Sharma, V., Davison, D., Ko, T., Bula, M., et al. (2021) · Scientific Data · doi:10.1038/s41597-021-01008-4 · Cited by 14
Daulatzai, M. A. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9528-x · Cited by 12
“Indeed, the single medication or single treatment modality has failed to ameliorate the heterogeneous pathologies encountered in AD (Aisen et al. 2008; Aisen and Vellas 2013; Doody et al. 2013; Lehrer and Rheinstein 2014).”
BackgroundEmerging structures and dynamic mechanisms of γ-secretase for Alzheimer’s disease
Miao, Y., & Wolfe, M. S. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01781 · Cited by 13
“However, GSEC inhibitors (GSIs) failed in clinical trials (Doody et al., 2013a), partly due to a lack of selectivity for APP over other substrates such as Notch (Doody et al., ; Coric et al., 2015).”
BackgroundLasheen, N. N., Allam, S., Elgarawany, A., Aswa, D. W., Mansour, R., & Farouk, Z. E. (2024) · The Journal of Physiological Sciences · doi:10.1186/s12576-024-00933-4 · Cited by 14
Unraveling the mystery of citrate transporters in Alzheimer’s disease: An updated review
Mukherjee, A. G., Mishra, S., Gopalakrishnan, A. V., Kannampuzha, S., Murali, R., Wanjari, U. R., Stany, B. K., Vellingiri, B., Madhyastha, H., Deepankumar, K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102726 · Cited by 12
Shadyab, A. H., Aslanyan, V., Jacobs, D. M., Salmon, D. P., Morrison, R. H., Katula, J. A., Jin, S., Thomas, R. G., LaCroix, A. Z., Pa, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70118 · Cited by 13
Self-citationTrkA-mediated endocytosis of p75-CTF prevents cholinergic neuron death upon γ-secretase inhibition
Franco, M. L., García-Carpio, I., Comaposada-Baró, R., Escribano-Saiz, J. J., Chávez‐Gutiérrez, L., & Vilar, M. (2021) · Life Science Alliance · doi:10.26508/lsa.202000844 · Cited by 16
“Thus, our results may also acquire particular significance in the context the failed phase III clinical trial with the GSI semagacestat, where the unexpected cognitive decline of the treated group was observed (Doody et al, 2013).”
Kim, M., & Борисович, Б. И. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032092 · Cited by 14
“Multiple clinical trials of γ-secretase inhibitors failed partly due to side effects resulting from the inhibition of cleavage of Notch receptor and other γ-secretase substrates, such as for example trial of semagacestat (LY-450139) [13].”
BackgroundHuang, T., Lin, Y., Chen, J., Hu, J., Chen, H., Zhang, Y., Zhang, B., & He, X. (2023) · Cancers · doi:10.3390/cancers15092623 · Cited by 19
ABC Transporter C1 Prevents Dimethyl Fumarate from Targeting Alzheimer’s Disease
Möhle, L., Stefan, K., Bascuñana, P., Brackhan, M., Brüning, T., Eiriz, I., Menuawy, A. E., van Genderen, S., Santos‐García, I., Górska, A. M., et al. (2023) · Biology · doi:10.3390/biology12070932 · Cited by 13
“However, the phase III trial was terminated due to severe side effects [12].”
BackgroundDirect reprogramming of induced neural progenitors: a new promising strategy for AD treatment
Lai, S., Zhang, M., Xu, D., Zhang, Y., Qiu, L., Tian, C., & Zheng, J. C. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0028-y · Cited by 12
“, Semagacestat presented side effect, such as skin cancers and infections [17-19].”
BackgroundC-Terminal Fragment, Aβ39–42-Based Tetrapeptides Mitigates Amyloid-β Aggregation-Induced Toxicity
Bansal, S., Maurya, I. K., Yadav, N., Thota, C. K., Kumar, V., Tikoo, K., Chauhan, V. S., & Jain, R. (2018) · ACS Omega · doi:10.1021/acsomega.8b01522 · Cited by 12
Tissue engineering scaffolds in the treatment of brain disorders in geriatric patients
Niri, A. D., Zarchi, A. A. K., Harati, P. G., Salimi, A., & Mujokoro, B. (2019) · Artificial Organs · doi:10.1111/aor.13485 · Cited by 15
Allosteric Modulators of Potential Targets Related to Alzheimer's Disease: a Review
Silva, G. M., Barcelos, M. P., Poiani, J. G. C., Hage-Melim, L. I. D. S., & da Silva, C. H. T. D. P. (2019) · ChemMedChem · doi:10.1002/cmdc.201900299 · Cited by 12
Kapoor, A., ONDRI Investigators, Bartha, R., Black, S. E., BORRIE, M. J., Freedman, M., Gao, F., Herrmann, N., Mandzia, J. L., Ozzoude, M., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191097 · Cited by 13
Wessels, A. M., Belger, M. A., Johnston, J. A., Yu, Y., Rentz, D. M., Dowsett, S. A., & Chandler, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220303 · Cited by 12
“To evaluate the impact of natural disease progression on health outcomes, the 18-month change on the iADRS was approximated based on placebo data from Lilly-sponsored AD treatment trials [5, 6, 18, 34] as 7 points for MCI due to AD, 14 points for mild AD dementia, and 21 points for moderate AD demen-”
MethodD’Avanzo, C., Sliwinski, C., Wagner, S. L., Tanzi, R. E., Kim, D. Y., & Kovacs, D. M. (2015) · The FASEB Journal · doi:10.1096/fj.15-271015 · Cited by 12
Modulators of Amyloid β-Protein (Aβ) Self-Assembly
Rahimi, F., Li, H. J., Sinha, S., & Bitan, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00006-x · Cited by 15
“…a major recent setback with the failure of semagacestat, which not only did not improve symptoms in patients with AD, but actually worsened symptoms (Doody et al., 2013). β-Secretase inhibitors are currently being tested in several clinical trials (Vassar, 2014), yet recent research showing that…”
BackgroundUltra-Early Phase pathologies of Alzheimer’s disease and other neurodegenerative diseases
Okazawa, H. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.022 · Cited by 12
Paradoxical effects of mutant ubiquitin on Aβ plaque formation in an Alzheimer mouse model
Verheijen, B. M., Stevens, J., Gentier, R. J. G., Hekke, C. D. V. ‘., van den Hove, D., Hermes, D. J. H. P., Steinbusch, H. W. M., Ruijter, J. M., Grimm, M. O. W., Haupenthal, V. J., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.011 · Cited by 14
Curcumin and Its Nanoformulations as Therapeutic for Alzheimer’s Disease
Kakkar, V., Kumari, P., Adlakha, S., & Kaur, I. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_14 · Cited by 13
Kajimoto, Y., Kameda, M., Kambara, A., Kuroda, K., Tsuji, S., Nikaido, Y., Saura, R., & Wanibuchi, M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.866352 · Cited by 14
The Epigenetics Orchestra of Notch Signaling: A Symphony for Cancer Therapy
Paniri, A., Hosseini, M. M., Amjadi‐Moheb, F., Tabaripour, R., Soleimani, E., Langroudi, M. P., Zafari, P., & Akhavan‐Niaki, H. (2023) · Epigenomics · doi:10.2217/epi-2023-0270 · Cited by 11
Structural basis of human γ-secretase inhibition by anticancer clinical compounds
Guo, X., Li, H., Lu, X., Liu, H., Kaicheng, U., Yan, C., Lei, J., Huang, J., Zhou, R., & Shi, Y. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01439-8 · Cited by 13
Guizzaro, L., Bałkowiec-Iskra, E., Haberkamp, M., Mol, P. G. M., Moreau, A., Mueller-Berghaus, J., Philadelphy, D., Balabanov, P. P., Garcia, J., Thirstrup, S., et al. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101644 · Cited by 14
A Pentacyclic Triterpene from Ligustrum lucidum Targets γ-Secretase
Luo, W., Ip, F. C. F., Fu, G., Cheung, K., Tian, Y., Hu, Y., Sinha, A., Cheng, E. Y. L., Wu, X., Bustos, V., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00389 · Cited by 11
Lye, S., Aust, C. E., Griffiths, L. R., & Fernandez, F. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117332 · Cited by 11
Understanding familial Alzheimer's disease: The fit‐stay‐trim mechanism of γ‐secretase
Mehra, R., & Kepp, K. P. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1556 · Cited by 13
Innate Immunity Protein IFITM3 in Alzheimer's Disease
Hur, J. (2021) · DNA and Cell Biology · doi:10.1089/dna.2021.0585 · Cited by 11
“However, the notch signaling related side effects in guts and the accumulation of APP-CTFs led to the pause of clinical trials (Coric et al. , 2012; Doody et al. , 2013).”
Amylin and Secretases in the Pathology and Treatment of Alzheimer’s Disease
Singh, S. P., Yang, F., Sivils, A., Cegielski, V., & Chu, X. (2022) · Biomolecules · doi:10.3390/biom12070996 · Cited by 11
“However, several strides have been made to establish BACE2′s role as a potential contributor to AD risk despite not having significant documentation of its function within the central nervous system (CNS).”
BackgroundInfluentialRe-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach
Haut, F., Argyrousi, E. K., & Arancio, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010259 · Cited by 11
“Similarly, despite the promising results in reducing A β production, clinical trials with the γ -secretase inhibitors semagacestat and avagacestat were discontinued due to serious side effects, such as the development of skin cancer and the worsening of cognitive performance [98,99].”
ResultBeggiato, S., Giuliani, A., Sivilia, S., Lorenzini, L., Antonelli, T., Imbimbo, B. P., Giardino, L., Calzà, L., & Ferraro, L. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.01.065 · Cited by 11
Biometals and Alzheimer’s Disease
Mot, A. I., & Crouch, P. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804562-6.00001-4 · Cited by 16
Jalali, D., Guevarra, J. A., Martinez, L., Hung, L., & Vonhoff, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137022 · Cited by 12
Alzheimer's disease: still a perplexing problem
Chinthapalli, K. (2014) · BMJ · doi:10.1136/bmj.g4433 · Cited by 11
The amyloid hypothesis is too good to be true
Kurkinen, M. T. (2017) · Alzheimer s Dementia & Cognitive Neurology · doi:10.15761/adcn.1000106 · Cited by 11
“Ten years later, EMA (European Medicines Agency) approved the use of memantine in Europe [75].”
BackgroundInfluentialDiscovery of the Oxadiazine FRM-024: A Potent CNS-Penetrant Gamma Secretase Modulator
Bursavich, M. G., Harrison, B. A., Acharya, R. A., Costa, D. E., Freeman, E. A., Hrdlicka, L., Jin, H. Y., Kapadnis, S., Moffit, J. S., Murphy, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00904 · Cited by 11
Alzheimer's Disease and Vascular Dementia, Connecting and Differentiating Features
Hurła, M., Banaszek, N., Kozubski, W. P., & Dorszewska, J. (2024) · Current Alzheimer Research · doi:10.2174/0115672050319219240711103459 · Cited by 10
Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis
Ito, D., & Okada, K. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52234 · Cited by 10
Giambra, V., Caldarelli, M., Franza, L., Rio, P., Bruno, G., Iasio, S. D., Mastrogiovanni, A., Gasbarrini, A., Gambassi, G., & Cianci, R. (2025) · Biomedicines · doi:10.3390/biomedicines13040768 · Cited by 11
“…γ -secretase [142] Dibenzazepine Inhibition of γ -secretase [142] MK-0752 Inhibition of γ -secretase [11] Semagacestat Inhibition of γ -secretase [143] INCB7839 ADAM inhibitor [146] CB-103 Inhibitors of formation [147] Brontictuzumab, Tarextumab Monoclonal antibodies [27,148] An intriguing study…”
A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials
Nallapu, B. T., Petersen, K. K., Qian, T., Demirsoy, İ., Ghanbarian, E., Davatzikos, C. A., Lipton, R. B., Ezzati, A., Initiative, A. D. N., Weiner, M. W., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213490 · Cited by 10
Self-citation
Metadata
- Authors
- Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., Aisen, P. S., Siemers, E., Sethuraman, G., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Hôpital de La Grave (FR)
- Boston Children's Hospital (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 341-350
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118935254
- Cited by
- 1,224
- References
- 24
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 85 · 2023: 84 · 2022: 93 · 2021: 91 · 2020: 140 · 2019: 118 · 2018: 109 · 2017: 99 · 2016: 106 · 2015: 88 · 2014: 77 · 2013: 22
- FWCI
- 68.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U19AG010483)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- semagacestat, Alzheimer's disease, gamma-secretase inhibitors, amyloid plaques, cognitive decline, activities of daily living, adverse events, skin cancer, lymphopenia, immunosuppression, drug safety, trial termination, dose comparison, ADAS-Cog, amyloid precursor protein, beta-secretase, gamma-secretase, treatment discontinuation
- MeSH terms
- Activities of Daily Living, Aged, Alanine, Alzheimer Disease, Azepines, Cognition, Double-Blind Method, Female, Humans, Male, Middle Aged, Skin Neoplasms, Biomarkers, Weight Loss, Amyloid beta-Peptides, Treatment Failure, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.